SERPINE1 -675 4G/5G polymorphism is associated with asthma severity and inhaled corticosteroid response

European Respiratory Journal

Volumn 38, Issue 5, 2011, Pages 1036-1043

  Dijkstra, A ^a   Postma, D S ^a   Bruinenberg, M ^a   Van Diemen, C C ^a   Boezen, H M ^a   Koppelman, G H ^a   Timens, W ^a   Vonk, J M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Asthma remission; Asthma severity; Genetic; Inhaled corticosteroids; Lung function decline; Plasminogen activator inhibitor 1

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN E;

ADULT; AGED; ARTICLE; ASTHMA; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HUMAN; LONGITUDINAL STUDY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; RISK ASSESSMENT; RISK FACTOR; SERPINE1 GENE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ASTHMA; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN E; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; REMISSION INDUCTION; RESPIRATORY FUNCTION TESTS;

EID: 80355129871     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00182410     Document Type: Article

References (62)

1. Grol MH, Gerritsen J, Vonk JM, et al. Risk factors for growth and decline of lung function in asthmatic individuals up to age 42 years. A 30-year follow-up study. Am J Respir Crit Care Med 1999; 160: 1830-1837. (Pubitemid 30004683)
2. Lange P, Parner J, Vestbo J, et al. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998; 339: 1194-1200.
3. Ulrik CS, Lange P. Decline of lung function in adults with bronchial asthma. Am J Respir Crit Care Med 1994; 150: 629-634. (Pubitemid 24291487)
4. Vonk JM, Jongepier H, Panhuysen CI, et al. Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up. Thorax 2003; 58: 322-327. (Pubitemid 36411418)
5. Dijkstra A, Vonk JM, Jongepier H, et al. Lung function decline in asthma: association with inhaled corticosteroids, smoking and sex. Thorax 2006; 61: 105-110. (Pubitemid 43235425)
6. Vonk JM, Postma DS, Boezen HM, et al. Childhood factors associated with asthma remission after 30 year follow up. Thorax 2004; 59: 925-929. (Pubitemid 39490774)
7. Panhuysen CI, Vonk JM, Koëter GH, et al. Adult patients may outgrow their asthma: a 25-year follow-up study. Am J Respir Crit Care Med 1997; 155: 1267-1272.
8. Broekema M, Timens W, Vonk JM, et al. Persisting remodeling and less airway wall eosinophil activation in complete remission of asthma. Am J Respir Crit Care Med 2010; 183: 310-316.
9. Elias JA, Zhu Z, Chupp G, et al. Airway remodeling in asthma. J Clin Invest 1999; 104: 1001-1006.
10. Busse WW, Lemanske RF Jr. Asthma. N Engl J Med 2001; 344: 350-362. (Pubitemid 32107645)
11. Tattersfield AE, Knox AJ, Britton JR, et al. Asthma. Lancet 2002; 360: 1313-1322. (Pubitemid 35284626)
12. Pampuch A, Kowal K, Bodzenta-Lukaszyk A, et al. The -675 4G/5G plasminogen activator inhibitor-1 promoter polymorphism in house dust mite-sensitive allergic asthma patients. Allergy 2006; 61: 234-238. (Pubitemid 43381836)
13. Kowal K, Zukowski S, Moniuszko M, et al. Plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in sputum of allergic asthma patients. Folia Histochem Cytobiol 2008; 46: 193-198.
14. Eitzman DT, McCoy RD, Zheng X, et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996; 97: 232-237. (Pubitemid 26021713)
15. Hattori N, Degen JL, Sisson TH, et al. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin Invest 2000; 106: 1341-1350.
16. Eddy AA, Fogo AB. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 2006; 17: 2999-3012. (Pubitemid 44707760)
17. Kucharewicz I, Kowal K, Buczko W, et al. The plasmin system in airway remodeling. Thromb Res 2003; 112: 1-7. (Pubitemid 38167577)
18. Cho SH, Tam SW, Demissie-Sanders S, et al. Production of plasminogen activator inhibitor-1 by human mast cells and its possible role in asthma. J Immunol 2000; 165: 3154-3161.
19. Xu J, Postma DS, Howard TD, et al. Major genes regulating total serum immunoglobulin E levels in families with asthma. Am J Hum Genet 2000; 67: 1163-1173.
20. Burzotta F, Di CA, Amore C, et al. 4G/5G promoter PAI-1 gene polymorphism is associated with plasmatic PAI-1 activity in Italians: a model of gene-environment interaction. Thromb Haemost 1998; 79: 354-358. (Pubitemid 28065884)
21. Dawson SJ, Wiman B, Hamsten A, et al. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268: 10739-10745. (Pubitemid 23162248)
22. Buckova D, Izakovicova HL, Vacha J. Polymorphism 4G/5G in the plasminogen activator inhibitor-1 (PAI-1) gene is associated with IgE-mediated allergic diseases and asthma in the Czech population. Allergy 2002; 57: 446-448. (Pubitemid 34442160)
23. Cho SH, Hall IP, Wheatley A, et al. Possible role of the 4G/5G polymorphism of the plasminogen activator inhibitor 1 gene in the development of asthma. J Allergy Clin Immunol 2001; 108: 212-214. (Pubitemid 32735403)
24. Cho SH, Ryu CH, Oh CK. Plasminogen activator inhibitor-1 in the pathogenesis of asthma. Exp Biol Med (Maywood) 2004; 229: 138-146. (Pubitemid 38146557)
25. Bajou K, Noel A, Gerard RD, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998; 4: 923-928. (Pubitemid 28364031)
26. Shapiro RL, Duquette JG, Roses DF, et al. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res 1996; 56: 3597-3604. (Pubitemid 26251658)
27. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature 1996; 383: 441-443. (Pubitemid 26330833)
28. de Vries K, Goei J, Booy-Noord H, et al. Changes during 24 hours in the lung function and histamine hyperreactivity of the bronchial tree in asthmatic and bronchitic patients. Int Arch Allergy Appl Immunol 1962; 20: 93-101.
29. Panhuysen CI, Bleecker ER, Koëter GH, et al. Characterization of obstructive airway disease in family members of probands with asthma. An algorithm for the diagnosis of asthma. Am J Respir Crit Care Med 1998; 157: 1734-1742.
30. van Diemen CC, Postma DS, Vonk JM, et al. A disintegrin and metalloprotease 33 polymorphisms and lung function decline in the general population. Am J Respir Crit Care Med 2005; 172: 329-333. (Pubitemid 41026143)
31. Jansen DF, Schouten JP, Vonk JM, et al. Smoking and airway hyperresponsiveness especially in the presence of blood eosinophilia increase the risk to develop respiratory symptoms: a 25-year follow-up study in the general adult population. Am J Respir Crit Care Med 1999; 160: 259-264. (Pubitemid 29326097)
32. van der Lende R, Orie NG. The MRC-ECCS questionnaire on respiratory symptoms (use in epidemiology). Scand J Respir Dis 1972; 53: 218-226.
33. Mensinga TT, Schouten JP, Rijcken B, et al. The relationship of eosinophilia and positive skin test reactivity to respiratory symptom prevalence in a community-based population study. J Allergy Clin Immunol 1990; 86: 99-107. (Pubitemid 20226850)
34. Rijcken B, Schouten JP, Weiss ST, et al. The relationship between airway responsiveness to histamine and pulmonary function level in a random population sample. Am Rev Respir Dis 1988; 137: 826-832. (Pubitemid 18099293)
35. Rijcken B, Weiss ST. Longitudinal analyses of airway responsiveness and pulmonary function decline. Am J Respir Crit Care Med 1996; 154: S246-S249.
36. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38: 963-974.
37. Kerstjens HA, Brand PL, Hughes MD, et al. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group. N Engl J Med 1992; 327: 1413-1419.
38. Kucukarabaci B, Gunes HV, Ozdemir G, et al. Investigation of association between plasminogen activator inhibitor type-1 (PAI-1) gene 4G/5G polymorphism frequency and plasma PAI-1 enzyme activity in patients with acute stroke. Genet Test 2008; 12: 443-451.
39. Stegnar M, Uhrin P, Peternel P, et al. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost 1998; 79: 975-979. (Pubitemid 28224735)
40. Leander K, Wiman B, Hallqvist J, et al. PAI-1 level and the PAI-14G/5G polymorphism in relation to risk of non-fatal myocardial infarction: results from the Stockholm Heart Epidemiology Program (SHEEP). Thromb Haemost 2003; 89: 1064-1071. (Pubitemid 36798159)
41. Stevens PT, Kicic A, Sutanto EN, et al. Dysregulated repair in asthmatic paediatric airway epithelial cells: the role of plasminogen activator inhibitor-1. Clin Exp Allergy 2008; 38: 1901-1910.
42. Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev 2002; 3: 85-101. (Pubitemid 34827150)
43. Margaglione M, Cappucci G, d'Addedda M, et al. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants. Arterioscler Thromb Vasc Biol 1998; 18: 562-567. (Pubitemid 28177895)
44. Vaisanen SB, Humphries SE, Luong LA, et al. Regular exercise, plasminogen activator inhibitor-1 (PAI-1) activity and the 4G/5G promoter polymorphism in the PAI-1 gene. Thromb Haemost 1999; 82: 1117-1120. (Pubitemid 29419729)
45. Bonfigli AR, Sirolla C, Cenerlli S, et al. Plasminogen activator inhibitor-1 plasma level increases with age in subjects with the 4G allele at position -675 in the promoter region. Thromb Haemost 2004; 92: 1164-1165. (Pubitemid 39545547)
46. Yarnell JW, Sweetnam PM, Rumley A, et al. Lifestyle and hemostatic risk factors for ischemic heart disease: the Caerphilly Study. Arterioscler Thromb Vasc Biol 2000; 20: 271-279. (Pubitemid 30048375)
47. Vignola AM, Riccobono L, Mirabella A, et al. Sputum metalloproteinase-9/ tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med 1998; 158: 1945-1950. (Pubitemid 29008837)
48. Andrade MV, Hiragun T, Beaven MA. Dexamethasone suppresses antigen-induced activation of phosphatidylinositol 3-kinase and downstreamresponses inmast cells. J Immunol 2004; 172: 7254-7262. (Pubitemid 38747584)
49. Berenstein EH, Garcia-Gil M, Siraganian RP. Dexamethasone inhibits receptor-activated phosphoinositide breakdown in rat basophilic leukemia (RBL-2H3) cells. J Immunol 1987; 138: 1914-1918. (Pubitemid 17040822)
50. Daëron M, Sterk AR, Hirata F, et al. Biochemical analysis of glucocorticoid-induced inhibition of IgE-mediated histamine release from mouse mast cells. J Immunol 1982; 129: 1212-1218.
51. Nakamura R, Okunuki H, Ishida S, et al. Gene expression profiling of dexamethasone-treated RBL-2H3 cells: induction of antiinflammatory molecules. Immunol Lett 2005; 98: 272-279. (Pubitemid 40602640)
52. Bator JM, Cohen RL, Chambers DA. Hydrocortisone regulates the dynamics of plasminogen activator and plasminogen activator inhibitor expression in cultured murine keratinocytes. Exp Cell Res 1998; 242: 110-119. (Pubitemid 28366526)
53. Samad F, Bergtrom G, Amrani DL. Regulation of plasminogen activation by interleukin-6 in human lung fibroblasts. Biochim Biophys Acta 1994; 1221: 307-314. (Pubitemid 24130874)
54. Van Zaane B, Nur E, Squizzato A, et al. Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors. J Thromb Haemost 2010; 8: 2483-2493.
55. Simon RH, Gross TJ, Edwards JA, et al. Fibrin degradation by rat pulmonary alveolar epithelial cells. Am J Physiol 1992; 262: L482-L488.
56. He G, Pedersen SB, Bruun JM, et al. Regulation of plasminogen activitor inhibitor-1 in human adipose tissue: interaction between cytokines, cortisol and oestrogen. Horm Metab Res 2000; 32: 515-520. (Pubitemid 32176080)
57. Kowal K, Bodzenta-Lukaszyk A, Pampuch A, et al. Plasminogen activator inhibitor-1 plasma concentration in allergic asthma patients during allergen challenge. Int Arch Allergy Immunol 2007; 144: 240-246. (Pubitemid 47587611)
58. Festa A, D'Agostino R, Jr, Rich SS, et al. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non- Hispanic whites: the Insulin Resistance Atherosclerosis Study. Circulation 2003; 107: 2422-2427. (Pubitemid 36605223)
59. Vercelli D. Genetics, epigenetics, and the environment: switching, buffering, releasing. J Allergy Clin Immunol 2004; 113: 381-386.
60. Barton SJ, Koppelman GH, Vonk JM, et al. PLAUR polymorphisms are associated with asthma, PLAUR levels, and lung function decline. J Allergy Clin Immunol 2009; 123: 1391-1400.
61. Dear AE, Medcalf RL The urokinase-type-plasminogen-activator receptor (CD87) is a pleiotropic molecule. Eur J Biochem 1998; 252: 185-193. (Pubitemid 28101992)
62. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3: 932-943. (Pubitemid 35477371)